An interventional study of European Study of screening for prostate cancer risk calculator in Prostate Cancer, sponsored by Norwegian University of Science and Technology. Recruiting at 3 sites in Norway. Open to male participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Prostatic Neoplasms with a site in Norway — 16 open to participants now, 27 under way, 9 of them phase 3. Prostatic Neoplasms · Norway.
Among the 85 studies in Prostatic Neoplasms with a site in Norway, this one is the 12th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 84th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →16 of the 85 studies in Prostatic Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
Bayer · Sites in Norway, Belgium, Finland and 13 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in Norway, United States, Argentina and 32 more countries
Ages 18+ · Men only
University of Alberta · Sites in Norway, United States, Canada and 2 more countries
Ages 50–70 · Men only · Healthy volunteers
University Hospital of North Norway · Sites in Norway
Men only
Oslo University Hospital · Sites in Norway
Ages 18+ · Men only · Healthy volunteers
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 50 Years to 75 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 24 · Phase 4 1
First in 1995; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,016 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 383 across the 66 interventional studies, 641 across the 18 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 85 have an industry lead sponsor. The 10 most frequent:
Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 47 are open to participants now.
Norwegian University of Science and Technology has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Prostatic Neoplasms with a site in Norway that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06935487Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 85 studies in Prostatic Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary. In others, the test is sufficiently elevated that men are referred for further investigations. Most men with an elevated PSA are offered an MRI examination of the prostate gland, and for some, a tissue sample of the prostate is also recommended if the suspicion of cancer is high enough. Although this comprehensive investigation reveals most clinically significant , or dangerous cases of cancer, many indolent, or "harmless" cancer cases are also detected, which would not have caused the man any harm during his lifetime (approximately 20% of all prostate cancer diagnoses diagnosed in current clinical practive). Cancer treatment is not recommended for such cases, but for many men, the diagnosis and subsequent follow-up can cause him and his family anxity and concern. In addition, prostate biopsies are unpleasant for the patient and the investigation process is resource-intensive for both the man and the health care service.
Risk stratification uses machine learning methods to better identify the men who require further investigations with MRI and tissue samples. In this project, the investigators investigate whether the best risk stratification tools are non-inferior in detecting clinically significant prostate cancer compared to current practice, and whether they lead to fewer tissue samples, MRI scans, less health anxiety, and better cost-effectiveness.
Background Prostate cancer (PCa) is the most common non-skin cancer among men. Most PCa cases are identified after an elevated prostate-specific antigen (PSA) level has been identified on blood testing. In most men this leads to a hospital referral, magnetic resonance imaging (MRI) of the prostate, and biopsy (tissue sampling) of the prostate in men where MRI is suggestive of a prostate cancer.
Although the PSA-test is the main method for identifying men who have prostate cancer, the test has low specificity, meaning that many men with an elevated PSA-level do not harbour PCa that will cause the man harm within his lifetime. In current clinical practice, such "false" PSA elevations can be difficult to distinguish from the "true" elevations found in men with clinically significant PCa (csPCa, Gleason >3+3) and therefore still lead to an MRI, and in many cases even a biopsy procedure is necessary to exclude csPCa.
Multivariable risk stratification uses the statistical methods of machine learning to quantify a man's probability of having prostate cancer based on other information that is available about the patient, which is known to affect the likelihood of him having prostate cancer. The aim of such stratification is to improve the identification of men who are likely to have prostate cancer, beyond the capacity of the unspecific PSA test, with its many false positives. This in order to improve identification of men who actually need further diagnostic testing, and to better distinguish these men from those men where the probability of significant disease is so low that further investigations can safely be omitted, without missing cases of significant disease.
Although such risk stratification tools have previously been developed, are readily available, and in retrospective studies have been demonstrated to reduce unnecessary MRIs and biopsies considerably, clinical uptake continues to be low due to the lack of prospective trials demonstrating efficacy and safety. As a result, at present, almost all men referred with a suspicion of prostate cancer undergo MRI and subsequent clinical assessment for biopsy. In health care settings where PCa-screening is implemented, as is a stated goal in the EU Council cancer screening guidelines, the number of men requiring diagnostic work-up will likely increase dramatically in ensuing years.
Knowledge gaps The risk calculators (RCs) stemming from the European Randomised Study of Screening for Prostate Cancer (ERSPC) are the currently best known and most utilised multivariable risk stratification tools. Their use has been retrospectively validated in multiple studies. All presently available development, and almost all validating studies are, however, hampered by their retrospective design and varying size which presently hinder widespread clinical implementation of this promising new method. In the only prospective study known to us, 47% of MRI investigations could be avoided compared with today's practice of performing an MRI in all men referred with an elevated PSA (>3ng/ml). However, this study was not designed to answer the primary research question of the present proposal, namely whether this RC approach gives csPCa detection that is non-inferior to performing an MRI in all referred men. As a result, although multivariable risk stratification of men with suspected PCa holds promise, whether the method gives non-inferior cancer detection to current practice represents a key knowledge gap which presently limits its implementation.
Study aims The primary objective of the current proposal is to perform the first prospective, adequately powered investigation of whether risk stratification using the risk stratification calculators from the European Randomised Study of Screening for Prostate Cancer study gives non-inferior detection of clinically significant prostate cancer compared with performing an MRI in all men referred with a suspicion of prostate cancer.
How clinical decision-making in men suspected of harbouring PCa affects men's health-related quality of life also has not been thoroughly investigated. And similarly, whether multivariable risk stratification is in fact cost-efficient compared with an MRI-all approach has not been conclusively determined in a prospective, clinical trial. The secondary aims of the study are to examine how the decision of whether to perform biopsy affects the health-related quality of life of men who undergo such consideration, and to prospectively determine the cost-efficiency of performing multivariable risk stratification, compared with performing an MRI in all men referred with a suspicion of prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single group
Device: European Study of screening for prostate cancer risk calculator
The ERSPC RCs are the currently best known and most utilised multivariable PCa risk stratification tools. All participating men undergo risk stratification by ERSPC RCs to determine need for MRI and for biopsy.
Also known as: https://www.prostatecancer-riskcalculator.com/, Rotterdam prostate cancer risk calculator
Detection of clinically significant prostate cancer
The study examines whether the risk calculator strategy gives non-inferior detection of csPCa compared with performing an MRI upfront in all men. csPCa defined as International society of Urological pathology grade group (ISUP GG) \>1.
Time frame: During the initial diagnostic work-up (up to 6 weeks)
Detection of clinically insignificant prostate cancer
The investigators will compare the number of patients with low grade (ISUP GG 1) prostate cancer detected by the upfront MRI vs upfront RC strategies
Time frame: During the initial diagnostic work-up (up to 6 weeks)
Numbers of prostate biopsy sessions required
Determine the number of prostata biopsy sessions required by the upfront MRI vs upfront RC strategies
Time frame: 1 year after completion of inclusion
Numbers of prostate MRIs required
Determine the number of prostate MRI scans required by the upfront MRI vs upfront RC strategies
Time frame: 1 year after completion of inclusion
Quality of life effect of decision to perfrom prostate biopsy
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 form. The EORTC QLQ-C30 (v3.0) scores 30 items into 5 functional scales, 9 symptom scales/items, and global health status (0-100 range). Higher scores indicate better functioning/QoL but worse symptoms.
Time frame: 1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: IPSS (International Prostate Symptom Score). Higher scores mean more symptoms. IPSS classifies symptoms as mild (0-7), moderate (8-19), or severe (20-35)
Time frame: 1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: IIEF-5 (International Index of Erectile Function) Lower IIEF-5 scores mean higher degree of erectile dysfunction
Time frame: 1 year after study inclusion is completed
Quality of life effect of decision to perfrom prostate biopsy
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Participants will be asked whether they are concerned about the possibility that they may have prostate cancer (yes/no), and about how concerned about the posibility they have cancer (no concerns, mild concerns, moderate concerns, severe concerns).
Time frame: 1 year after study inclusion is completed
Cost-effectiveness assessment
Determine cost-effectivenes of upfront MRI vs upfront RC. The investigators will determine the incremental cost-effectiveness ratio (ICER) and the net monetary benefit (NMB)
Time frame: 1 year after completion of inclusion
Perilesional biopsy results
Targeted biopsies will be taken from PI-RADS 3-5 lesions on MRI. Additional biopsies are to be taken from the area of prostate surrounding the lesion in the prostate seen on MRI, as per current European Urological Association guidelines. The study will assess the value of perilesional biopsies by recording the detection of prostate cancer in such perilesional biopsies.
Time frame: During the initial diagnostic work up (up to 6 weeks)
Quality of life effect of decision to perfrom prostate biopsy
The investigators assess the health-related quality of life effect of the decision to perform biopsy in men referred with suspected prostate cancer. Questionnaire that will be used to assess participants' quality of life: The Memorial Anxiety Scale for Prostate Cancer (MAX-PC). An 18-item, validated questionnaire designed to measure cancer-specific anxiety in men, specifically covering prostate cancer anxiety, prostate-specific antigen sampling anxiety, and fear of cancer recurrence. Higher scores mean higher degree of anxiety relating to prostate cancer and to prostate-specific antigen testing.
Time frame: 1 year after study inclusion is completed.
Plan to share: Yes — Sharing of anonmous data for scientific purposeswill be considered upon reasonable request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 21 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →